CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 164 enrolled
Drug / intervention
Nitrofurantoin 100 MG +1 moredrug
Likely dose
Nitrofurantoin 100 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03287089
NCT03287089Phase 4Completed

Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial

Wake Forest University Health Sciences·interventional·Posted Sep 19, 2017·Updated Aug 9, 2022

In Brief

A Phase 4 clinical trial evaluating Nitrofurantoin 100 MG and Placebo Oral Tablet for Catheter-Associated Urinary Tract Infection. Completed, enrolled 164 participants across 1 site.

Detailed Summary

The specific aim of this randomized double-blind placebo-controlled trial is to evaluate the efficacy of administration of nitrofurantoin prophylaxis after catheter discontinuation for the prevention of catheter-associated urinary tract infections in patients with postoperative short-term catheterization following pelvic reconstructive surgery and/or urinary incontinence surgery. Patients that undergo pelvic organ prolapse and/or urinary incontinence surgery and fail their post-operative voiding trial will be included in the study. Upon successfully passing and in-office voiding trial at the time of catheter removal, they will be randomized to either nitrofurantoin 100mg twice daily or an identical appearing placebo capsule twice daily for 5 days following catheter removal. The primary outcome will be the treatment of clinically suspected and/or culture-proven UTI within 30 days of surgery. Secondary outcomes include adverse events associated with nitrofurantoin use and medication compliance. Primary and secondary outcomes will be evaluated with Student t test and chi squared or Fisher exact test as appropriate. Assuming a decrease in symptomatic UTIs attributable to nitrofurantoin prophylaxis from 32% to 14%, with 80% power, and a two-sided alpha of 0.05, we should recruit a total of 164 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 19, 2017
Enrollment StartSep 29, 2017
Primary CompletionMay 30, 2019
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.8 years ago

Interventions

Nitrofurantoin 100 MGdrug

Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days

Placebo Oral Tabletdrug

Matching placebo